

## Orkambi

## **Prior Authorization Request**

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-866-249-6155**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-866-814-5506**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do not call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name:		Date:Patient's Date of Birth:
Specialty:Physician Office Telephone:		NPI#:Physician Office Fax:
1.	What is the diagnosis? ☐ Cystic fibrosis ☐ Other	
2.	What is the ICD-10 code?	
3.	Is the patient currently receiving therapy with the r	requested medication? $\square$ Yes $\square$ No If No, skip to #6
4.	Is the patient currently receiving the requested medication through samples or a manufacturer's patient assistance program? <i>If Yes or Unknown, skip to #6</i> $\square$ Yes $\square$ No $\square$ Unknown	
5.	Is the patient experiencing a benefit from therapy with the requested medication as evidenced by disease stability of disease improvement (e.g., improvement in FEV1 from baseline)? $\square$ Yes $\square$ No No further questions	
6.		in the cystic fibrosis transmembrane conductance regulator tach genetic testing report.   Yes  No  Unknown
7.	Is the patient homozygous or heterozygous for the ☐ Homozygous ☐ Heterozygous ☐ No F508del mutation	F508del mutation?
8.	Will the requested medication be used in combinat ☐ Yes ☐ No	tion with any other medication containing ivacaftor?
	ttest that this information is accurate and true formation is available for review if requested b	
	escriber or Authorized Signature	Date (mm/dd/vv)

Send completed form to: Case Review Unit CVS Caremark Prior Authorization Fax: 1-866-249-6155

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Orkambi SGM - 10/2022.